Amarin Corp Plc (AMRN)

[KCSVEN]

I think you overestimate the sales forces ability to sell and inferior drug in a market already established with competitors. I'm not even sure they will make much effort, I think this is just a first step towards a combo drug for them and,again, pretty sure the Marine market is much smaller than estimates and Vascepa sales will mainly be in Anchor-where the bulk of sales for Lovaza currently are at and where Lovaza and Epanova will be uncovered by insurance..

I've been on board with partner vs GIA on Anchor, of course forever sub $10 would not be longer than 2018 as Reduce It will be everything. Positive Reduce It stock would be 100, negative would be a stock killer.

But I agree a non-partner Anchor launch could keep the stock price sub 10 for awhile unless they can prove they can sell the drug and get sales while a BP partner puts it above 10 easy right away assuming it is a reasonable deal.